IL-10 derived from M2 macrophage promotes cancer stemness via JAK1/STAT1/NF-κB/Notch1 pathway in non-small cell lung cancer.
Li YangYing DongYanjun LiDong WangShasha LiuDan WangQun GaoShaofei JiXinfeng ChenQingyang LeiWenyi JiangLiping WangBin ZhangJane J YuYi ZhangPublished in: International journal of cancer (2019)
Tumor-associated macrophages (TAMs), key immune cells in the tumor microenvironment, are shown to be closely correlated with the progression of non-small cell lung cancer (NSCLC). Cancer stem cells (CSCs) can contribute to NSCLC progression as well. We aimed to clarify whether TAMs promote the progression of NSCLC by mainly affecting the activities of CSCs. We found that TAM-like cells promoted CSC-like properties in NSCLC cells in vitro, which was mediated by TAM-derived IL-10. TAM-derived IL-10 promoted CSC-like properties of NSCLC cells through JAK1/STAT1/NF-κB/Notch1 signaling. Blockade of IL-10/JAK1 signaling inhibited TAM-mediated NSCLC tumor growth in vivo, and the TAM-mediated expression of CSC-related and mesenchymal-related genes in NSCLC. Lastly, expression levels of these signaling molecules were significantly correlated with survival of NSCLC patients. Therefore, IL-10/JAK1 signaling might be a potential therapeutic target for NSCLC treatment.
Keyphrases
- small cell lung cancer
- advanced non small cell lung cancer
- cancer stem cells
- brain metastases
- induced apoptosis
- poor prognosis
- stem cells
- signaling pathway
- end stage renal disease
- chronic kidney disease
- bone marrow
- newly diagnosed
- risk assessment
- squamous cell carcinoma
- long non coding rna
- prognostic factors
- peritoneal dialysis
- young adults
- endoplasmic reticulum stress
- childhood cancer